Ifinatamab deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with pretreated extensive stage...

Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously...

Antengene’s ATG-022 (CLDN18.2 ADC) granted Breakthrough Therapy Designation for the treatment of gastric/gastroesophageal junction adenocarcinoma

LM-302 (CLDN18.2 ADC), a class 1 new drug, has again been granted Breakthrough Therapy designation,...

Mabwell’s CDH17-targeting ADC 7MW4911 receives IND clearance from FDA

Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum